Introduction
============

Breast cancer is the most common malignancy and the leading cause of cancer death in women worldwide.[@b1-ott-11-5451] Despite recent progresses in its treatment, the prognosis of breast cancer remains unsatisfactory.[@b2-ott-11-5451] This is mainly due to the lack of specific and effective prognostic factors. It is necessary to explore more reliable biomarkers that are strongly associated with the progression and prognosis of breast cancer. Recent research has suggested that the expression of CD44 variant isoform v6 (CD44v6) may be one of the potential prognostic biomarkers for breast cancer.[@b3-ott-11-5451],[@b4-ott-11-5451]

CD44 is a cell surface glycoprotein and plays critical roles in cell motility, proliferation, and survival.[@b5-ott-11-5451],[@b6-ott-11-5451] CD44v6 is the chief variant isoform of CD44 and regulates tumor invasion and metastasis.[@b7-ott-11-5451],[@b8-ott-11-5451] In fact, CD44v6 can regulate extracellular matrix and suppress tumor apoptosis by PI2K/Akt and MAPK activation.[@b9-ott-11-5451],[@b10-ott-11-5451] The prognostic value of CD44v6 has been reported in various types of tumors, including gastric cancer, hepatocellular carcinoma, esophageal cancer, lung cancer, head and neck squamous cell carcinoma, and osteosarcoma.[@b11-ott-11-5451]--[@b16-ott-11-5451] With respect to breast cancer, the relationship between CD44v6 and prognosis was still controversial.[@b17-ott-11-5451]--[@b19-ott-11-5451] To address this issue, we conducted a meta-analysis of all the eligible studies to evaluate the predictive value of CD44v6 in clinicopathological features and prognosis of breast cancer.

Materials and methods
=====================

Search strategy
---------------

We searched literature from PubMed, Cochrane Database, and EMBASE database up to January 2018. The following search terms were used: breast cancer and CD44v6 and prognosis or survival. The language was limited to English.

Inclusion criteria
------------------

The studies selected in this meta-analysis were randomized-controlled studies or observational studies (case--control or cohort) that evaluated the relationship between CD44v6 expression and the clinicopathological features or prognosis of breast cancer. Eligible studies met the following criteria: 1) patients were pathologically confirmed to have breast cancer; 2) CD44v6 expression was evaluated by immunohistochemistry (IHC); and 3) the association of CD44v6 expression with clinicopathological features and prognosis was analyzed.

Exclusion criteria
------------------

Studies were excluded on the basis of the following criteria: 1) review articles or letters; 2) the study of CD44v6 mRNA expression by RT-PCR; 3) insufficient data to determine the prognostic value of CD44v6; and 4) studies with fewer than 20 analyzed patients.

Data extraction and quality assessment
--------------------------------------

The following data of the eligible studies were independently extracted by two reviewers (Guang-Lei Qiao and Li-Na Song): first author, country, publication year, number of patients, numbers of different clinicopathological parameters, detection method, cutoff, follow-up period, and prognostic outcomes (overall survival \[OS\], disease-free survival \[DFS\]).

The quality of the included studies was assessed by the Newcastle--Ottawa Scale criteria. High-quality studies refer to those scored 5 or above 5.

Statistical analysis
--------------------

The estimated OR was used to summarize the relationship between CD44v6 expression and the clinicopathological features of breast cancer. The HR and 95% CI were used to summarize the effect measures for the OS and DFS. If the HR and 95% CI were not reported in the original study, these values were estimated from available data using software designed by Tierney et al.[@b20-ott-11-5451] The subgroup analyses were performed by ethnicity. All statistical values were reported with the two-sided *P*-value threshold for statistical significance set at 0.05. Heterogeneity was evaluated with the *Q* test and *I*^2^ statistic. When heterogeneity was absent (*I*^2^\<50%), a fixed-effects model was used. Otherwise, a random-effects model was used. Publication bias was analyzed using Egger's test and Begg's test. One-way sensitivity analyses were performed to evaluate the stability of the meta-analysis results. Analysis was performed using STATA 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Selection and characteristics of the studies
--------------------------------------------

After the systematic literature search, 98 potentially relevant papers were retrieved. By screening the titles and abstracts, 60 potential studies were retrieved. Then, 47 studies were excluded because they were not written in English (20 studies), used RT-PCR for studying CD44v6 mRNA expression (two studies), had insufficient data to conduct meta-analysis (23 studies), included fewer than 20 patients (one study), or had IHC cutoff \>50% (one study). Finally, 13 articles were included in the final meta-analysis, comprising 1,458 patients ([Figure 1](#f1-ott-11-5451){ref-type="fig"}).[@b3-ott-11-5451],[@b4-ott-11-5451],[@b21-ott-11-5451]--[@b31-ott-11-5451] The population was from Asia and Europe (China, Japan, Germany, Ireland, Austria, Bulgaria, France, and the Netherlands). The detailed characteristics of the studies are summarized in [Table 1](#t1-ott-11-5451){ref-type="table"}.

Meta-analysis results
=====================

Correlation of CD44v6 with clinicopathological features
-------------------------------------------------------

The forest plot of OR was evaluated for the relationship between CD44v6 expression and clinicopathological features including age, tumor diameter, histological type and grade, pTNM stage, lymph node metastasis, and menopausal status. In pooled analysis, CD44v6 expression was significantly associated with histological grade (overall: OR=1.56, 95% CI \[1.06, 2.29\], *P*=0.023; Asian: OR=1.78, 95% CI \[1.12, 2.85\], *P*=0.016, fixed-effect) ([Figure 2A](#f2-ott-11-5451){ref-type="fig"}) and lymph node metastasis (overall: OR=1.96, 95% CI \[1.01, 3.78\], *P*=0.046; Asian: OR=2.11, 95% CI \[1.00, 4.44\], *P*=0.049, random-effect) ([Figure 2B](#f2-ott-11-5451){ref-type="fig"}) in breast cancer. However, we did not find that CD44v6 expression was associated with age, tumor diameter, histological type, pTNM stage, and menopausal status. These results are summarized in [Table 2](#t2-ott-11-5451){ref-type="table"}.

The prognostic effect of CD44v6 on survival in breast cancer
------------------------------------------------------------

Survival analysis was performed on HR for OS and DFS in eight (730 patients) and three (247 patients) studies, respectively. The pooled analysis revealed that CD44v6 expression was highly correlated with poor OS (HR=1.55, 95% CI \[1.09, 2.22\], *P*=0.015, fixed-effect) ([Figure 3](#f3-ott-11-5451){ref-type="fig"}), but not with poor DFS (HR=1.06, 95% CI \[0.37, 3.07\], *P*=0.909, random-effect).

In the subgroup analysis, we found the significant prognostic effect of CD44v6 expression in Asian patients (OS: HR=2.22, 95% CI \[1.34, 3.68\], *P*=0.002, fixed-effect) ([Table 2](#t2-ott-11-5451){ref-type="table"}).

Publication bias and sensitivity analyses
-----------------------------------------

Begg's test and Egger's test were performed to evaluate the publication bias. There was no evidence of publication bias for the pooled analysis of OS (*P*~Begg~=0.536, *P*~Egger~=0.733) ([Figure 4A](#f4-ott-11-5451){ref-type="fig"}) and DFS (*P*~Begg~=1, *P*~Egger~=0.781) ([Figure 4B](#f4-ott-11-5451){ref-type="fig"}). Sensitivity analyses were performed by excluding one study in turn to check whether individual study affected the final results. All the results were not materially altered.

Discussion
==========

Breast cancer remains the most common cancer in woman. Despite remarkable progresses in its treatment, the prognosis is still not optimistic.[@b2-ott-11-5451] Prognostic factors are correlated with some clinical outcomes, such as OS or DFS, independent of any treatment. The accumulating evidence showed that CD44v6 might be a potential prognostic marker for solid tumors.[@b13-ott-11-5451]--[@b16-ott-11-5451] There are many reports about the prognostic significance of CD44v6 in breast cancer. However, the results were inconsistent. Therefore, the quantitative meta-analysis about the association of CD44v6 with prognostic factor in breast cancer is required. This is the first meta-analysis to evaluate the clinicopathological features and prognostic significance of CD44v6 in breast cancer by summarizing all relevant studies.

We performed a comprehensive meta-analysis to assess the association between CD44v6 expression and clinicopathological features of breast cancer. The results showed that CD44v6 expression was significantly associated with histological grade and lymph node metastasis. However, no correlation was observed between CD44v6 expression and age, tumor diameter, histological type, pTNM stage, or menopausal status. Our results suggested that the expression of CD44v6 in tumor cells might enhance their potential for metastasis in the regional lymph nodes. Günthert et al[@b7-ott-11-5451] found that transfection of tumor cells with CD44v6 could enhance metastasis to lymph nodes. Kaufmann et al[@b31-ott-11-5451] demonstrated that CD44v6 could help tumor cells escape the immune system to promote lymph node metastasis. Thus, our results are in line with those of basic studies. CD44v6 expression may be considered as a marker of breast cancer that indicates lymph node metastasis. However, the correlation of CD44v6 expression with tumor diameter, pTNM stage, or menopausal status was not observed. These might be due to the different sample cohorts studied, as well as the smaller number of studies included.

The pooled data showed promising prognostic effect of CD44v6 expression in breast cancer samples for OS. The patients with CD44v6 expression had a 1.55 times higher risk of poor prognosis than those without CD44v6 expression. The subgroup analysis based on ethnicity was conducted to further evaluate prognostic value of CD44v6. The results showed that patients with CD44v6 expression had poor OS in the Asian subgroup. This may be attributed to the differences in gene and environment among the ethnicity. These results were consistent with prior reports of meta-analysis in gastric cancer,[@b13-ott-11-5451] pharyngolaryngeal cancer,[@b32-ott-11-5451] colorectal cancer,[@b33-ott-11-5451] hepatocellular carcinoma,[@b14-ott-11-5451] esophageal cancer,[@b15-ott-11-5451] and osteosarcoma.[@b16-ott-11-5451]

The glycoprotein CD44 is a receptor for extracellular matrix components and is the most common cancer stem cell (CSC) marker in multiple types of cancers.[@b34-ott-11-5451] CD44 is a complex family of molecules, including standard isoform of CD44 (CD44s) and CD44v1-v10 isoform. To date, only the particular variant CD44v6 was found to be related to aggressive tumor behavior and prognosis in breast cancer.[@b31-ott-11-5451],[@b35-ott-11-5451] This meta-analysis revealed that CD44v6 expression was associated with histological grade, lymph node metastasis, and poor prognosis in breast cancer. CD44v6 also has great implications for targeted therapy and prognostic imaging. Qian et al found an antihuman CD44v6 functionalized nanoparticle for targeted drug delivery to pancreatic cancer, resulting in tumor cell apoptosis.[@b36-ott-11-5451] The CD44v6 monoclonal antibody-conjugated nanoprobes showed excellent stability, targeting ability against CD44-expressing gastric CSC, high photothermal conversion, and ablation ability. The CD44v6 nanoprobes exhibited potential for applications of gastric cancer targeted imaging and photothermal therapy.[@b37-ott-11-5451] In head and neck squamous cell carcinoma, bivatuzumab could direct mertansine activity to CD44v6-expressing tumor cells. Although effective, the greatly toxic payload resulted in skin toxicity and termination of the program.[@b38-ott-11-5451]

There are limitations to this meta-analysis. First, the population data were extracted from the included studies and individual data were unavailable. Second, the heterogeneity could not be eliminated, and we used the random-effects model to obtain more conservative estimates. Third, due to lack of available data, we were unable to perform subgroup analyses based on breast cancer subtypes (ER/PR/HER2 negative or positive). Despite these limitations, this meta-analysis is the first study to analyze the prognostic value of CD44v6 expression in breast cancer.

Conclusion
==========

This meta-analysis showed that CD44v6 expression is significantly associated with a poor survival, histological grade, and lymph node metastasis in breast cancer patients, especially among Asian patients. These results should be confirmed by adequate, high-quality, well-designed multicenter studies.
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###### 

Associations of CD44v6 expression with clinicopathological features. (**A**) Histological grade. (**B**) Lymph node metastasis.

**Note:** [Figure 2B](#f2-ott-11-5451){ref-type="fig"} used random effects model.
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![Funnel plot analysis (**A**: OS; **B**: DFS).\
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###### 

Baseline characteristics of the included studies

  Study                               Country           Ethnicity   Year   Antibody     Cutoff      Number of patients   Number of positives   Tumor stage   OM        Follow-up
  ----------------------------------- ----------------- ----------- ------ ------------ ----------- -------------------- --------------------- ------------- --------- ----------------------
  Wu et al[@b21-ott-11-5451]          China             Asian       2015   Maxim        ≥10%        60                   37                    I--IV         NR        NR
  Shah et al[@b4-ott-11-5451]         India             Asian       2010   Novacastra   \>0%        85                   40                    II--IV        NR        NR
  Yu et al[@b3-ott-11-5451]           China             Asian       2010   Dako         ≥25%        98                   38                    I--III        OS, DFS   36 (8--65) months
  Ma et al[@b22-ott-11-5451]          China             Asian       2005   R&D          ≥5%         78                   43                    I--III        OS        5 years
  Morris et al[@b23-ott-11-5451]      Ireland           European    2001   BioGenex     \>10%       109                  87                    NR            OS        5 years
  Bànkfalvi et al[@b24-ott-11-5451]   Germany           European    1998   Bender       ≥5%         54                   26                    NR            OS, DFS   Max: 109 months
  Jansen et al[@b25-ott-11-5451]      the Netherlands   European    2001   R&D          \>5%        338                  219                   NR            DFS       128 (61--170) months
  Tokue et al[@b26-ott-11-5451]       Japan             Asian       1998   Dako         \>5%        95                   72                    I--IV         OS        80 months
  Charpin et al[@b27-ott-11-5451]     France            European    1997   R&D          \>0%        218                  119                   NR            NR        NR
  Gao et al[@b28-ott-11-5451]         China             Asian       2016   NA           \>3 score   96                   56                    I--IV         OS        5 years
  Umeda et al[@b29-ott-11-5451]       Japan             Asian       2016   Abcam        \>5%        21                   21                    NR            NR        NR
  Tempfer et al[@b30-ott-11-5451]     Austria           European    1996   Bender       \>3 score   115                  28                    NR            OS        78 (11--172) months
  Kaufmann et al[@b31-ott-11-5451]    Germany           European    1995   Dako         \>5%        91                   76                    NR            OS        35 (6--90) months

**Abbreviations:** DFS, disease-free survival; NR, not reported; Max, maximum; OM, outcome measured; OS, overall survival.

###### 

Detailed results of subgroup analyses for clinicopathological features and prognostic significance

  Clinicopathological features        Number of studies   Number of patients   Total, OR (95% CI), *P*-value   Ethnicity, OR (95% CI), *P*-value   
  ----------------------------------- ------------------- -------------------- ------------------------------- ----------------------------------- -------------------------------
  Age (\<50 years vs ≥50 years)       5                   790                  0.88 (0.65, 1.21), *P*=0.44     1.19 (0.73, 1.96), *P*=0.481        0.72 (0.48, 1.08), *P*=0.115
  Tumor diameter (\<2 cm vs ≥2 cm)    4                   321                  1.82 (0.51, 6.47), *P*=0.356    1.82 (0.51, 6.47), *P*=0.356        --
  Histological type (IDC vs others)   6                   888                  1.23 (0.64, 2.37), *P*=0.535    1.21 (0.38, 3.89), *P*=0.743        1.21 (0.38, 3.06), *P*=0.681
  Histological grade (III vs I+II)    6                   620                  1.56 (1.06, 2.29), *P*=0.023    1.78 (1.12, 2.85), *P*=0.016        1.2 (0.62, 2.32), *P*=0.59
  pTNM stage (III/IV vs I/II)         5                   416                  1.45 (0.59, 3.55), *P*=0.414    1.45 (0.59, 3.55), *P*=0.414        --
  Lymph node metastasis (yes vs no)   8                   1,191                1.96 (1.01, 3.78), *P*=0.046    2.11 (1.00, 4.44), *P*=0.049        1.61 (0.25, 10.15), *P*=0.613
  Menopausal status (pre vs post)     3                   258                  1.36 (0.80, 2.31), *P*=0.262    1.36 (0.80, 2.31), *P*=0.262        --
  OS                                  8                   736                  1.55 (1.09, 2.22), *P*=0.015    2.22 (1.34, 3.68), *P*=0.002        1.09 (0.66, 1.81), *P*=0.725
  DFS                                 3                   490                  1.06 (0.37, 3.07), *P*=0.909    0.72 (0.41, 1.25), *P*=0.241        --

**Abbreviations:** DFS, disease-free survival; IDC, invasive ductal carcinoma; OS, overall survival; --, no results due to insufficient studies.
